Bifeprunox versus placebo for schizophrenia

Chattopadhyay, Arka; Frey, Stephen; Green, Ghiselle

doi:10.1002/14651858.cd012029.pub2

Cited by 8 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up until today (28 February 2020), this classification effort has detected new comparisons for review titles, new classes of drugs and new qualifiers from existing RCTs. These discoveries were assessed by Cochrane editors and led to start and, in some cases, accomplishment of at least 14 Cochrane reviews: six on qualifiers (Abbas et al, 2017; Hanafi et al, 2017; Latifeh et al, 2019; Turk, Alkhatib, et al, 2017; Turk, Zuhri Yafi, et al, 2017; Turkmani et al, 2019), one on a class of drugs (Karl et al, 2018) and nine on comparing two drugs (Bazrafshan et al, 2015; Chattopadhyay et al, 2016; Eslami Shahrbabaki et al, 2018; Ibragimov et al, 2019; Mazhari et al, 2017; Nikvarz et al, 2017; Nur & Adams, 2016; Schmidt et al, 2019; Zare & Bazrafshan, 2017).…”

Section: Discussionmentioning

confidence: 99%

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

Shokraneh

Adams

2021

Health Info Libraries J

View full text Add to dashboard Cite

Background Systematic reviewing is a time‐consuming and resource‐intensive process. Information specialists are maintaining study‐based registers to facilitate efficient conduct of systematic reviews. Classification of study‐level meta‐data ‐such as interventions –can result in much more accurate searches, saving time in the early steps of systematic reviewing. Objective To classify all pharmacological interventions from all schizophrenia trials. Methods We used Cochrane Schizophrenia's Study‐based Register as the source of trials, Emtree and MeSH for synonyms, AdisInsight and http://CT.gov for research drugs and WHO ATC for marketed drugs. Results One third of tested interventions on patients with schizophrenia are pharmacological (816; belonging to 106 clinical classes) with antipsychotic drugs being the most researched (15.1%). Only 528 of these medications are listed in WHO ATC. Around one third of these drug interventions are seen only in research (236; from 21 pharmacological/biochemical classes). Within the pharmacological interventions, we identified 28 ‘qualifiers’ including dose, route and timing of drug delivery. Conclusion Identification and classification of pharmacological interventions from trials require use of many sources of information none of which are inclusive of all drugs. Limitations of each source are helpful to understand. Classification of non‐pharmacological interventions is now a priority for clinical and information scientists and professionals.

show abstract

Section: Discussionmentioning

confidence: 99%

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

Shokraneh

Adams

2021

Health Info Libraries J

View full text Add to dashboard Cite

show abstract

“…Bifeprunox, an atypical antipsychotic drug designed for schizophrenia, [129] has completed a phase‐II study in which efficiency and effect in bipolar depression were determined (NCT00245973). Lumateperone in phase‐III clinical studies showed marked improvement with CDSS scores in bipolar depression (NCT03249376) [130] .…”

Section: Piperazine Derivatives In Clinical Trials For Depressionmentioning

confidence: 99%

Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure‐Activity Relationships

et al. 2021

View full text Add to dashboard Cite

Depression is the single largest contributor to global disability with a huge economic and social burden on the world. There are a number of antidepressant drugs on the market, but treatment‐resistant depression and relapse of depression in a large number of patients have increased problems for clinicians. One peculiarity observed in most of the marketed antidepressants is the presence of a piperazine substructure. Although piperazine is also used in the optimization of other pharmacological agents, it is almost extensively used for the development of novel antidepressants. One common understanding is that this is due to its favorable CNS pharmacokinetic profile; however, in the case of antidepressants, piperazine plays a much bigger role and is involved in specific binding conformations of these agents. Therefore, in this review, a critical analysis of the significance of the piperazine moiety in the development of antidepressants has been performed. An overview of current developments in the designing and synthesis of piperazine‐based antidepressants (2015 onwards) along with SAR studies is also provided. The various piperazine‐based therapeutic agents in early‐ or late‐phase human testing for depression are also discussed. The preclinical compounds discussed in this review will help researchers understand how piperazine actually influences the design and development of novel antidepressant compounds. The SAR studies discussed will provide crucial clues about the structural features and optimizations required to enhance the efficacy and potency of piperazine‐based antidepressants.

show abstract

“…The remaining 5 reviews reported searching websites in the Potential biases section. 26,[55][56][57][58] This was usually a statement that websites were searched for unpublished literature to counteract bias in the published literature.…”

Section: Location Of Details Reportedmentioning

confidence: 99%

A review of the reporting of web searching to identify studies for Cochrane systematic reviews

Briscoe

2017

Research Synthesis Methods

View full text Add to dashboard Cite

The literature searches that are used to identify studies for inclusion in a systematic review should be comprehensively reported. This ensures that the literature searches are transparent and reproducible, which is important for assessing the strengths and weaknesses of a systematic review and re-running the literature searches when conducting an update review. Web searching using search engines and the websites of topically relevant organisations is sometimes used as a supplementary literature search method. Previous research has shown that the reporting of web searching in systematic reviews often lacks important details and is thus not transparent or reproducible. Useful details to report about web searching include the name of the search engine or website, the URL, the date searched, the search strategy, and the number of results. This study reviews the reporting of web searching to identify studies for Cochrane systematic reviews published in the 6-month period August 2016 to January 2017 (n = 423). Of these reviews, 61 reviews reported using web searching using a search engine or website as a literature search method. In the majority of reviews, the reporting of web searching was found to lack essential detail for ensuring transparency and reproducibility, such as the search terms. Recommendations are made on how to improve the reporting of web searching in Cochrane systematic reviews.

show abstract

Bifeprunox versus placebo for schizophrenia

Cited by 8 publications

References 63 publications

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure‐Activity Relationships

A review of the reporting of web searching to identify studies for Cochrane systematic reviews

Contact Info

Product

Resources

About